Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron transdermal patch for prevention of nausea and vomiting during multi-day chemotherapy
ChiCTR1900022133Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Complete response during overall prevention evaluation period. Started Apr 2019; status: recruiting.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR1900022133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022133.